scholarly journals Persistence of rabies antibody 5 years after pre-exposure prophylaxis with human diploid cell antirabies vaccine and antibody response to a single booster dose

1987 ◽  
Vol 99 (1) ◽  
pp. 91-95 ◽  
Author(s):  
F. M. Rodrigues ◽  
V. B. Mandke ◽  
M. Roumiantzeff ◽  
C. V. R. Mohan Rao ◽  
J. M. Mehta ◽  
...  

SUMMARYIn 1978, 22 staff members of the National Institute of Virology, Pune, India, were given two doses of human diploid cell antirabies vaccine (HDCV) for primary pre-exposure prophylactic immunization; the interval between the two doses being approximately 4 weeks. Eighteen of these 22 vaccinees were given a booster dose 1 year later. All 18 vaccinees developed protective levels of antibody; most of them had antibody levels exceeding 10 IU/ml.In 1984, 5 years after the booster dose, 11 (79·0%) of 14 vaccinees tested still possessed neutralizing antibody levels ranging from 0·5 IU/ml to 10 IU/ml. Fourteen days after the administration of a booster dose, the antibody levels ranged from 10 to ≥ 100 IU/ml for all except one vaccinee (5·2 IU/ml). These findings demonstrate that the majority of vaccinees retained detectable neutralizing antibody after pre-exposure prophylaxis for as long as 5 years and that a single booster dose thereafter evoked a good antibody response.

1986 ◽  
Vol 35 (3) ◽  
pp. 663-670 ◽  
Author(s):  
Daniel B. Fishbein ◽  
Kenneth W. Bernard ◽  
Lawrence B. Schonberger ◽  
John W. Sumner ◽  
Robert A. Parker ◽  
...  

Vaccine ◽  
2011 ◽  
Vol 29 (21) ◽  
pp. 3742-3745 ◽  
Author(s):  
Ahmad Fayaz ◽  
Susan Simani ◽  
Alireza Janani ◽  
Firouzeh Farahtaj ◽  
Peyvand Biglari ◽  
...  

2022 ◽  
Author(s):  
Apoorva Munigela ◽  
Sasikala M ◽  
Gujjarlapudi Deepika ◽  
Anand V Kulkarni ◽  
Krishna Vemula ◽  
...  

Abstract Coronavirus disease (COVID-19) continues to be a major health concern leading to substantial mortality and morbidity across the world. Vaccination is effective in reducing the severity and associated mortality. Data pertaining to the duration of immunity, antibody waning and the optimal timing of booster dose administration is limited. In this cross-sectional study, we assessed the antibody levels in healthcare workers who were fully vaccinated after obtaining Institutional ethics committee approval and informed consent. Whole blood was collected and enumeration of S1/S2 neutralizing antibody levels was carried out using LIAISON SARS-COV-2 S1/S2 IgG assay. A total of 1636 individuals who were vaccinated with Covaxin or Covishield were included. Of these, 52% were males with a median age of 29 years. Diabetes and Hypertension was noted in 2.32% (38/1636) and 2.87% (47/1636) of the individuals. Spike neutralizing antibodies were below the detectable range (<15 AU/ml) in 6.0% (98/1636) of the individuals. Decline in neutralizing antibody was seen in 30% of the individuals above 40 years of age with comorbidities (diabetes and hypertension) after 6 months. These individuals may be prioritized for a booster dose at 6 months.


The Lancet ◽  
1983 ◽  
Vol 322 (8345) ◽  
pp. 301-304 ◽  
Author(s):  
M.J. Warrell ◽  
Pravan Suntharasamai ◽  
Abha Sinhaseni ◽  
Rod Phanfung ◽  
J-C. Vincent-Falquet ◽  
...  

1982 ◽  
Vol 89 (1) ◽  
pp. 101-110 ◽  
Author(s):  
G. S. Turner ◽  
K. G. Nicholson ◽  
D. A. J. Tyrrell ◽  
F. Y. Aoki

SUMMARYThe antibody responses of 194 volunteers were studied for up to 3 years after primary immunization with one, two or three doses of human diploid cell rabies vaccine, administered either in 0·1 ml volumes intradermally (i.d.) or as 1·0 ml intramuscularly (i.m.). Sero-conversion occurred in 95% of subjects after the first injection and in 100% after the second. The highest titres and most durable antibody responses were induced by three injections of vaccine.Booster doses were administered either by the subcutaneous (s.c.) or i.d. route, after 6, 12 or 24 months to randomly grouped volunteers; these induced responses ≥ 5·0 i.u. per ml in 95% of subjects. The responses were rapid and were neither influenced by the primary regimen nor by the timing and route of the booster dose.Antibody titres after i.d. immunization were only two-fold lower than those induced by the larger volume of vaccine. The findings suggest that the i.d. route is both effective and economic.


2006 ◽  
Vol 8 (3) ◽  
pp. 122-126 ◽  
Author(s):  
Anthony W. Gherardin ◽  
David J. Scrimgeour ◽  
Sonny C. Lau ◽  
Margaret A. Phillips ◽  
Robert B. Kass

Vaccine ◽  
1989 ◽  
Vol 7 (5) ◽  
pp. 437-442 ◽  
Author(s):  
Daniel B. Fishbein ◽  
David W. Dreesen ◽  
Dorothy F. Holmes ◽  
Richard E. Pacer ◽  
Allyn B. Ley ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document